Serum uromodulin and progression of kidney disease in patients with chronic kidney disease
dc.contributor.author | Lv, Li | |
dc.contributor.author | Wang, Jinwei | |
dc.contributor.author | Gao, Bixia | |
dc.contributor.author | Wu, Liang | |
dc.contributor.author | Wang, Fang | |
dc.contributor.author | Cui, Zhao | |
dc.contributor.author | He, Kevin | |
dc.contributor.author | Zhang, Luxia | |
dc.contributor.author | Chen, Min | |
dc.contributor.author | Zhao, Ming-Hui | |
dc.date.accessioned | 2018-11-26T10:30:17Z | |
dc.date.available | 2018-11-26T10:30:17Z | |
dc.date.issued | 2018-11-19 | |
dc.identifier.citation | Journal of Translational Medicine. 2018 Nov 19;16(1):316 | |
dc.identifier.uri | https://doi.org/10.1186/s12967-018-1693-2 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/146520 | |
dc.description.abstract | Abstract Background Uromodulin is specifically synthesized and secreted by kidney tubular epithelial cells. Studies on the association of serum uromodulin and outcomes of chronic kidney disease (CKD) are lacking. This study aimed to evaluate whether serum uromodulin was associated with outcomes of patients with CKD. Methods We measured serum uromodulin concentrations by ELISA in 2652 CKD patients from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE) and investigated the association of serum uromodulin with outcomes of CKD patients, including end-stage kidney disease (ESKD) receiving kidney replacement therapy, cardiovascular events and mortality by Cox proportional hazards regression model. Results A total of 2652 CKD patients were enrolled in this study, with an age of 48.7 ± 13.8 years and the baseline eGFR of 49.6 ± 29.4 mL/min/1.73 m2, of whom 58.4% were male. The median level of urinary albumin/creatinine ratio and serum uromodulin was 473.7 mg/g (IQR 134.1–1046.6 mg/g) and 77.2 ng/mL (IQR 48.3–125.9 ng/mL), respectively. Altogether, 404 ESKD, 189 cardiovascular events, and 69 deaths occurred during the median follow-up of 53.6 (IQR 44.0–64.0) months. Lower levels of serum uromodulin were independently associated with higher risk of incident ESKD after adjusting for traditional cardiovascular risk factors, with the hazard ratios (HRs) of 3.23 (95% confidence intervals [CIs] 2.15–4.85) for the middle tertile and 7.47 (95% CI 5.06–11.03) for the bottom tertile, compared with top tertile and 0.31 (95% CI 0.25–0.38) per every standard deviation increase. After further adjustment for the baseline eGFR, the association was greatly attenuated, but still significant, with HRs of 1.92 (95% CI 1.26–2.90) for the bottom tertile compared with top tertile and 0.69 (95% CI 0.55–0.86) per every standard deviation increase. Conclusions Serum uromodulin is independently associated with an increased risk of incident ESKD in CKD patients. | |
dc.title | Serum uromodulin and progression of kidney disease in patients with chronic kidney disease | |
dc.type | Article | en_US |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/146520/1/12967_2018_Article_1693.pdf | |
dc.language.rfc3066 | en | |
dc.rights.holder | The Author(s) | |
dc.date.updated | 2018-11-26T10:30:24Z | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.